Identification

Name
Sodium bicarbonate
Accession Number
DB01390
Type
Small Molecule
Groups
Approved
Description

Sodium bicarbonate is a white, crystalline powder that is commonly used as a pH buffering agent, an electrolyte replenisher, systemic alkalizer and in topical cleansing solutions.

Structure
Thumb
Synonyms
  • Baking soda
  • Bicarbonate of soda
  • Carbonic acid monosodium salt
  • e 500
  • e-500
  • e500
  • NaHCO3
  • Natriumhydrogenkarbonat
  • Sodium acid carbonate
  • Sodium bicarbonate
  • Sodium hydrogen carbonate
  • Sodium hydrogencarbonate
External IDs
B1654 / E-500(II) / INS NO.500(II) / INS-500(II)
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
800 Sodium Bicarbonate PowderPowder, for solution650 gHemodialysisBaxter Laboratories1988-12-31Not applicableCanada
BibagPowder, for solution650 gHemodialysisFresenius Medical Care Deutchland Gmbh2009-12-10Not applicableCanada
Bicarb Hemodial Conc 81.25gm/lLiquid81.25 gHemodialysisBicarbolyte Corporation1986-12-311998-06-08Canada
Bicarbolyte Bicar Hemodialysis ConcLiquid72 gHemodialysisBicarbolyte Corporation1986-12-311998-06-08Canada
Bicarbonate Conc Mb-330 Pwr 650mg/pckPowder650 gHemodialysisRenal Systems, Division Of Minntech Corp.1985-12-311998-11-02Canada
Bicarbonate Concentrate 4105Liquid80.68 gHemodialysisBaxter Laboratories1988-12-312002-08-01Canada
Bicarbonate Concentrate B38Solution80.7 gHemodialysisChief Medical Supplies Ltd2005-07-04Not applicableCanada
Bicarbonate Concentrate D17000Solution81.3 gHemodialysisBaxter Laboratories1986-12-31Not applicableCanada
BicartPowder1250 gHemodialysisBaxter Laboratories2013-10-22Not applicableCanada
BicartPowder650 gHemodialysisBaxter Laboratories1990-12-31Not applicableCanada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
medPREDkitKitMed Arbor Llc2017-12-25Not applicableUs
Sodium BicarbonateInjection, solution84 mg/mLIntravenousGeneral Injectables & Vaccines2010-08-01Not applicableUs
Sodium BicarbonateInjection, solution75 mg/mLIntravenousHospira, Inc.2006-05-18Not applicableUs
Sodium BicarbonateInjection, solution42 mg/mLIntravenousHospira, Inc.2017-01-012017-11-09Us
Sodium BicarbonateInjection84 mg/mLIntravenousInternational Medication Systems, Limited2000-06-01Not applicableUs
Sodium BicarbonateInjection, solution84 mg/mLIntravenousHospira, Inc.2006-05-18Not applicableUs
Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
After Bite KidsLiquid5 g/100gTopicalTender Corporation2014-11-26Not applicableUs
After Bite SensitiveLiquid5 g/100gTopicalTender Corporation2014-11-26Not applicableUs
After Bite the Itch EraserLiquid50 mg/mLTopicalTender Corporation2014-09-02Not applicableUs
After Bite The Itch Eraser KIDSLiquid5 g/100gTopicalTender Corporation2014-11-262016-10-29Us
Anti-EmpachoLiquid525 mg/15mLOralMenper Distributors2012-02-21Not applicableUs
Arm and Hammer Baking SodaPowder, for solution1 g/gOralChurch & Dwight Company, Inc.2000-01-01Not applicableUs
Assured Bug Bite ReliefLiquid5 g/100mLTopicalHuijing (Shanghai) Bio Tech Co., Ltd2017-08-01Not applicableUs
Assured Bug Bite ReliefLiquid5 g/100gTopicalShanghai Weierya Daily Chemicals Factory2015-11-10Not applicableUs
Baking Soda USPPowder100 %OralRegal Pharms, Division Of Bradcan Corporation1987-12-311996-12-16Canada
Brioschi Effervescent AntacidGranule, effervescent1.02 g/5gOralNeobourne Pharma Lp2015-06-30Not applicableUs
Unapproved/Other Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Assured Bug Bite ReliefLiquid5 g/100gTopicalShanghai Weierya Daily Chemicals Factory2015-11-10Not applicableUs
Medis Sodium BicarbonatePowder1000 mg/gOralHumco Holding Group. Inc.2017-11-092020-04-30Us
NeutInjection, solution.2 g/5mLIntravenousGeneral Injectables & Vaccines2014-07-31Not applicableUs
Neut Sodium BicarbonateInjection, solution.2 g/5mLIntravenousCardinal Health2005-08-22Not applicableUs
Neut Sodium BicarbonateInjection, solution.2 g/5mLIntravenousHospira, Inc.2005-08-22Not applicableUs
Premier Value Sodium BicarbonatePowder1000 mg/gOralChain Drug Consortium2017-10-27Not applicableUs
Sodium BicarbonateInjection84 mg/mLParenteralAmphastar Pharmaceuticals, Inc.2000-06-012016-12-06Us
Sodium BicarbonateInjection, solution42 mg/mLIntravenousGeneral Injectables & Vaccines2010-03-01Not applicableUs
Sodium BicarbonateInjection, solution84 mg/mLIntravenousHospira, Inc.1984-04-13Not applicableUs
Sodium BicarbonateInjection, solution84 mg/mLIntravenousRemedy Repack2015-03-072016-03-29Us
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Accusol 35 K0Sodium bicarbonate (12.9 g) + Calcium Chloride (0.343 g) + Magnesium chloride (0.136 g) + Sodium Chloride (7.66 g)SolutionHemodialysisChief Medical Supplies Ltd2007-10-31Not applicableCanada
Accusol 35 K2Sodium bicarbonate (12.9 g) + Calcium Chloride (0.343 g) + D-glucose (1.33 g) + Magnesium chloride (0.136 g) + Potassium Chloride (0.199 g) + Sodium Chloride (7.66 g)SolutionHemodialysisChief Medical Supplies LtdNot applicableNot applicableCanada
Accusol 35 K4Sodium bicarbonate (12.9 g) + Calcium Chloride (0.343 g) + D-glucose (1.33 g) + Magnesium chloride (0.136 g) + Potassium Chloride (0.398 g) + Sodium Chloride (7.66 g)SolutionHemodialysisChief Medical Supplies Ltd2007-10-31Not applicableCanada
Alka SeltzerSodium bicarbonate (1916 mg/1) + Acetylsalicylic acid (325 mg/1) + Citric Acid (1000 mg/1)Tablet, effervescentOralSalimex, S.A.2012-10-10Not applicableUs
Alka SeltzerSodium bicarbonate (1916 mg/1) + Acetylsalicylic acid (325 mg/1) + Citric Acid (1000 mg/1)Tablet, effervescentOralSalimex, S.A.2012-10-10Not applicableUs
Alka Seltzer EvtSodium bicarbonate (1.916 g) + Acetylsalicylic acid (325 mg) + Citric Acid (1 g)Tablet, effervescentOralMiles Inc. Pharmaceutical Division1977-12-311996-09-09Canada
Alka Seltzer FlavouredSodium bicarbonate (1.71 g) + Acetylsalicylic acid (325 mg) + Citric Acid (1.22 g)Tablet, effervescentOralMiles Inc. Pharmaceutical Division1986-12-311996-09-09Canada
Alka Seltzer OriginalSodium bicarbonate (1916 mg/1) + Acetylsalicylic acid (325 mg/1) + Citric Acid (1000 mg/1)TabletOralNavajo Manuracturing Company2016-09-16Not applicableUs
Alka-SeltzerSodium bicarbonate (1916 mg) + Acetylsalicylic acid (325 mg) + Citric Acid (1000 mg)Tablet, effervescentOralBayer1995-12-31Not applicableCanada
Alka-SeltzerSodium bicarbonate (1916 mg/1) + Acetylsalicylic acid (325 mg/1) + Citric Acid (1000 mg/1)Tablet, effervescentOralLil' Drug Store Products, Inc.2000-01-01Not applicableUs
Categories
UNII
8MDF5V39QO
CAS number
144-55-8
Weight
Average: 84.0066
Monoisotopic: 83.982338573
Chemical Formula
CHNaO3
InChI Key
UIIMBOGNXHQVGW-UHFFFAOYSA-M
InChI
InChI=1S/CH2O3.Na/c2-1(3)4;/h(H2,2,3,4);/q;+1/p-1
IUPAC Name
sodium hydrogen carbonate
SMILES
[Na+].OC([O-])=O

Pharmacology

Indication

Sodium bicarbonate is used for the treatment of metabolic acidosis which may occur in severe renal disease, uncontrolled diabetes, circulatory insufficiency due to shock or severe dehydration, extracorporeal circulation of blood, cardiac arrest and severe primary lactic acidosis. Also is indicated in severe diarrhea which is often accompanied by a significant loss of bicarbonate. Further indicated in the treatment of certain drug intoxications, including barbiturates (where dissociation of the barbiturateprotein complex is desired), in poisoning by salicylates or methyl alcohol and in hemolytic reactions requiring alkalinization of the urine to diminish nephrotoxicity of blood pigments.

Structured Indications
Pharmacodynamics

Intravenous sodium bicarbonate therapy increases plasma bicarbonate, buffers excess hydrogen ion concentration, raises blood pH and reverses the clinical manifestations of acidosis.

Mechanism of action

Sodium bicarbonate is a systemic alkalizer, which increases plasma bicarbonate, buffers excess hydrogen ion concentration, and raises blood pH, thereby reversing the clinical manifestations of acidosis. It is also a urinary alkalizer, increasing the excretion of free bicarbonate ions in the urine, thus effectively raising the urinary pH. By maintaining an alkaline urine, the actual dissolution of uric acid stones may be accomplished. Sodium bicarbonate acts as an antacid and reacts chemically to neutralize or buffer existing quantities of stomach acid but has no direct effect on its output. This action results in increased pH value of stomach contents, thus providing relief of hyperacidity symptoms. [PharmGKB]

TargetActionsOrganism
AHydrogen ions
neutralizer
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
16-BromoepiandrosteroneThe bioavailability of 16-Bromoepiandrosterone can be decreased when combined with Sodium bicarbonate.Investigational
19-norandrostenedioneThe bioavailability of 19-norandrostenedione can be decreased when combined with Sodium bicarbonate.Experimental, Illicit
2,5-Dimethoxy-4-ethylamphetamineSodium bicarbonate may decrease the excretion rate of 2,5-Dimethoxy-4-ethylamphetamine which could result in a higher serum level.Experimental, Illicit
2,5-Dimethoxy-4-ethylthioamphetamineSodium bicarbonate may decrease the excretion rate of 2,5-Dimethoxy-4-ethylthioamphetamine which could result in a higher serum level.Experimental
3,4-MethylenedioxyamphetamineSodium bicarbonate may decrease the excretion rate of 3,4-Methylenedioxyamphetamine which could result in a higher serum level.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamineSodium bicarbonate may decrease the excretion rate of 4-Bromo-2,5-dimethoxyamphetamine which could result in a higher serum level.Experimental, Illicit
5-androstenedioneThe bioavailability of 5-androstenedione can be decreased when combined with Sodium bicarbonate.Experimental, Illicit
AcepromazineSodium bicarbonate can cause a decrease in the absorption of Acepromazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
AceprometazineSodium bicarbonate can cause a decrease in the absorption of Aceprometazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
AcetazolamideThe risk or severity of adverse effects can be increased when Acetazolamide is combined with Sodium bicarbonate.Approved, Vet Approved
AlclometasoneThe bioavailability of Alclometasone can be decreased when combined with Sodium bicarbonate.Approved
AldosteroneThe bioavailability of Aldosterone can be decreased when combined with Sodium bicarbonate.Experimental, Investigational
AlimemazineSodium bicarbonate can cause a decrease in the absorption of Alimemazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
AllopurinolSodium bicarbonate can cause a decrease in the absorption of Allopurinol resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
AmcinonideThe bioavailability of Amcinonide can be decreased when combined with Sodium bicarbonate.Approved
AmphetamineSodium bicarbonate may decrease the excretion rate of Amphetamine which could result in a higher serum level.Approved, Illicit
AndrostenedioneThe bioavailability of Androstenedione can be decreased when combined with Sodium bicarbonate.Experimental, Illicit
AnecortaveThe bioavailability of Anecortave can be decreased when combined with Sodium bicarbonate.Investigational
anecortave acetateThe bioavailability of anecortave acetate can be decreased when combined with Sodium bicarbonate.Investigational
AtamestaneThe bioavailability of Atamestane can be decreased when combined with Sodium bicarbonate.Investigational
AtazanavirSodium bicarbonate can cause a decrease in the absorption of Atazanavir resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
AtorvastatinThe serum concentration of Atorvastatin can be decreased when it is combined with Sodium bicarbonate.Approved
Beclomethasone dipropionateThe bioavailability of Beclomethasone dipropionate can be decreased when combined with Sodium bicarbonate.Approved, Investigational
BenzphetamineSodium bicarbonate may decrease the excretion rate of Benzphetamine which could result in a higher serum level.Approved, Illicit
BetamethasoneThe bioavailability of Betamethasone can be decreased when combined with Sodium bicarbonate.Approved, Vet Approved
BisacodylThe therapeutic efficacy of Bisacodyl can be decreased when used in combination with Sodium bicarbonate.Approved
Bismuth SubcitrateThe therapeutic efficacy of Bismuth Subcitrate can be decreased when used in combination with Sodium bicarbonate.Approved
BL-1020Sodium bicarbonate can cause a decrease in the absorption of BL-1020 resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
BosutinibThe serum concentration of Bosutinib can be decreased when it is combined with Sodium bicarbonate.Approved
BudesonideThe bioavailability of Budesonide can be decreased when combined with Sodium bicarbonate.Approved
CaptoprilThe serum concentration of Captopril can be decreased when it is combined with Sodium bicarbonate.Approved
CefditorenThe serum concentration of Cefditoren can be decreased when it is combined with Sodium bicarbonate.Approved
CefpodoximeThe serum concentration of Cefpodoxime can be decreased when it is combined with Sodium bicarbonate.Approved, Vet Approved
CefuroximeThe serum concentration of Cefuroxime can be decreased when it is combined with Sodium bicarbonate.Approved
CerivastatinThe serum concentration of Cerivastatin can be decreased when it is combined with Sodium bicarbonate.Withdrawn
ChloroquineThe serum concentration of Chloroquine can be decreased when it is combined with Sodium bicarbonate.Approved, Vet Approved
ChlorphentermineSodium bicarbonate may decrease the excretion rate of Chlorphentermine which could result in a higher serum level.Illicit, Withdrawn
ChlorproethazineSodium bicarbonate can cause a decrease in the absorption of Chlorproethazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
ChlorpromazineSodium bicarbonate can cause a decrease in the absorption of Chlorpromazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
ChlortetracyclineSodium bicarbonate can cause a decrease in the absorption of Chlortetracycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational, Vet Approved
CiclesonideThe bioavailability of Ciclesonide can be decreased when combined with Sodium bicarbonate.Approved, Investigational
CinoxacinSodium bicarbonate can cause a decrease in the absorption of Cinoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational, Withdrawn
ClobetasolThe bioavailability of Clobetasol can be decreased when combined with Sodium bicarbonate.Investigational
Clobetasol propionateThe bioavailability of Clobetasol propionate can be decreased when combined with Sodium bicarbonate.Approved
ClobetasoneThe bioavailability of Clobetasone can be decreased when combined with Sodium bicarbonate.Approved
ClocortoloneThe bioavailability of Clocortolone can be decreased when combined with Sodium bicarbonate.Approved
Cortexolone 17α-propionateThe bioavailability of Cortexolone 17α-propionate can be decreased when combined with Sodium bicarbonate.Investigational
CorticosteroneThe bioavailability of Corticosterone can be decreased when combined with Sodium bicarbonate.Experimental
Cortisone acetateThe bioavailability of Cortisone acetate can be decreased when combined with Sodium bicarbonate.Approved
CysteamineThe therapeutic efficacy of Cysteamine can be decreased when used in combination with Sodium bicarbonate.Approved, Investigational
Dabigatran etexilateThe serum concentration of Dabigatran etexilate can be decreased when it is combined with Sodium bicarbonate.Approved
DabrafenibThe serum concentration of Dabrafenib can be decreased when it is combined with Sodium bicarbonate.Approved
DasatinibSodium bicarbonate can cause a decrease in the absorption of Dasatinib resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
DeferiproneThe serum concentration of Deferiprone can be decreased when it is combined with Sodium bicarbonate.Approved
DeflazacortThe bioavailability of Deflazacort can be decreased when combined with Sodium bicarbonate.Approved, Investigational
DelavirdineThe serum concentration of Delavirdine can be decreased when it is combined with Sodium bicarbonate.Approved
DemeclocyclineSodium bicarbonate can cause a decrease in the absorption of Demeclocycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
DesonideThe bioavailability of Desonide can be decreased when combined with Sodium bicarbonate.Approved, Investigational
DesoximetasoneThe bioavailability of Desoximetasone can be decreased when combined with Sodium bicarbonate.Approved
Desoxycorticosterone acetateThe bioavailability of Desoxycorticosterone acetate can be decreased when combined with Sodium bicarbonate.Approved
Desoxycorticosterone PivalateThe bioavailability of Desoxycorticosterone Pivalate can be decreased when combined with Sodium bicarbonate.Experimental, Vet Approved
DexamethasoneThe bioavailability of Dexamethasone can be decreased when combined with Sodium bicarbonate.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe bioavailability of Dexamethasone isonicotinate can be decreased when combined with Sodium bicarbonate.Vet Approved
DexmethylphenidateSodium bicarbonate can cause an increase in the absorption of Dexmethylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.Approved
DextroamphetamineSodium bicarbonate may decrease the excretion rate of Dextroamphetamine which could result in a higher serum level.Approved, Illicit
DiethylpropionSodium bicarbonate may decrease the excretion rate of Diethylpropion which could result in a higher serum level.Approved, Illicit
DiflorasoneThe bioavailability of Diflorasone can be decreased when combined with Sodium bicarbonate.Approved
DifluocortoloneThe bioavailability of Difluocortolone can be decreased when combined with Sodium bicarbonate.Approved, Investigational, Withdrawn
DifluprednateThe bioavailability of Difluprednate can be decreased when combined with Sodium bicarbonate.Approved
Dipotassium phosphateSodium bicarbonate can cause a decrease in the absorption of Dipotassium phosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
DoxycyclineSodium bicarbonate can cause a decrease in the absorption of Doxycycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational, Vet Approved
ElvitegravirThe serum concentration of Elvitegravir can be decreased when it is combined with Sodium bicarbonate.Approved
EnoxacinSodium bicarbonate can cause a decrease in the absorption of Enoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
EquileninThe bioavailability of Equilenin can be decreased when combined with Sodium bicarbonate.Experimental
EquilinThe bioavailability of Equilin can be decreased when combined with Sodium bicarbonate.Approved
ErlotinibThe serum concentration of Erlotinib can be decreased when it is combined with Sodium bicarbonate.Approved, Investigational
EstroneThe bioavailability of Estrone can be decreased when combined with Sodium bicarbonate.Approved
Estrone sulfateThe bioavailability of Estrone sulfate can be decreased when combined with Sodium bicarbonate.Approved
FexofenadineThe serum concentration of Fexofenadine can be decreased when it is combined with Sodium bicarbonate.Approved
FlecainideSodium bicarbonate may decrease the arrhythmogenic activities of Flecainide.Approved, Withdrawn
FleroxacinSodium bicarbonate can cause a decrease in the absorption of Fleroxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
FluasteroneThe bioavailability of Fluasterone can be decreased when combined with Sodium bicarbonate.Investigational
FludrocortisoneThe bioavailability of Fludrocortisone can be decreased when combined with Sodium bicarbonate.Approved
FlumequineSodium bicarbonate can cause a decrease in the absorption of Flumequine resulting in a reduced serum concentration and potentially a decrease in efficacy.Withdrawn
FlumethasoneThe bioavailability of Flumethasone can be decreased when combined with Sodium bicarbonate.Approved, Vet Approved
FlunisolideThe bioavailability of Flunisolide can be decreased when combined with Sodium bicarbonate.Approved, Investigational
Fluocinolone AcetonideThe bioavailability of Fluocinolone Acetonide can be decreased when combined with Sodium bicarbonate.Approved, Investigational, Vet Approved
FluocinonideThe bioavailability of Fluocinonide can be decreased when combined with Sodium bicarbonate.Approved, Investigational
FluocortoloneThe bioavailability of Fluocortolone can be decreased when combined with Sodium bicarbonate.Approved, Withdrawn
FluorometholoneThe bioavailability of Fluorometholone can be decreased when combined with Sodium bicarbonate.Approved
FluphenazineSodium bicarbonate can cause a decrease in the absorption of Fluphenazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
FluprednideneThe bioavailability of Fluprednidene can be decreased when combined with Sodium bicarbonate.Approved, Withdrawn
FluprednisoloneThe bioavailability of Fluprednisolone can be decreased when combined with Sodium bicarbonate.Approved
FlurandrenolideThe bioavailability of Flurandrenolide can be decreased when combined with Sodium bicarbonate.Approved
Fluticasone furoateThe bioavailability of Fluticasone furoate can be decreased when combined with Sodium bicarbonate.Approved
Fluticasone propionateThe bioavailability of Fluticasone propionate can be decreased when combined with Sodium bicarbonate.Approved
FluvastatinThe serum concentration of Fluvastatin can be decreased when it is combined with Sodium bicarbonate.Approved
FormestaneThe bioavailability of Formestane can be decreased when combined with Sodium bicarbonate.Approved, Investigational, Withdrawn
FosinoprilThe serum concentration of Fosinopril can be decreased when it is combined with Sodium bicarbonate.Approved
GabapentinThe serum concentration of Gabapentin can be decreased when it is combined with Sodium bicarbonate.Approved, Investigational
GarenoxacinSodium bicarbonate can cause a decrease in the absorption of Garenoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
GatifloxacinSodium bicarbonate can cause a decrease in the absorption of Gatifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
GefitinibThe serum concentration of Gefitinib can be decreased when it is combined with Sodium bicarbonate.Approved, Investigational
GemifloxacinSodium bicarbonate can cause a decrease in the absorption of Gemifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
GepefrineSodium bicarbonate may decrease the excretion rate of Gepefrine which could result in a higher serum level.Experimental
GrepafloxacinSodium bicarbonate can cause a decrease in the absorption of Grepafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational, Withdrawn
HalcinonideThe bioavailability of Halcinonide can be decreased when combined with Sodium bicarbonate.Approved, Investigational, Withdrawn
HE3286The bioavailability of HE3286 can be decreased when combined with Sodium bicarbonate.Investigational
HydrocortisoneThe bioavailability of Hydrocortisone can be decreased when combined with Sodium bicarbonate.Approved, Vet Approved
HydroxyamphetamineSodium bicarbonate may decrease the excretion rate of Hydroxyamphetamine which could result in a higher serum level.Approved
HyoscyamineThe serum concentration of Hyoscyamine can be decreased when it is combined with Sodium bicarbonate.Approved
Iofetamine I-123Sodium bicarbonate may decrease the excretion rate of Iofetamine I-123 which could result in a higher serum level.Approved
IsoniazidSodium bicarbonate can cause a decrease in the absorption of Isoniazid resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
IstaroximeThe bioavailability of Istaroxime can be decreased when combined with Sodium bicarbonate.Investigational
ItraconazoleThe serum concentration of Itraconazole can be decreased when it is combined with Sodium bicarbonate.Approved, Investigational
KetoconazoleThe serum concentration of Ketoconazole can be decreased when it is combined with Sodium bicarbonate.Approved, Investigational
LedipasvirThe serum concentration of Ledipasvir can be decreased when it is combined with Sodium bicarbonate.Approved
LevofloxacinSodium bicarbonate can cause a decrease in the absorption of Levofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
LisdexamfetamineSodium bicarbonate may decrease the excretion rate of Lisdexamfetamine which could result in a higher serum level.Approved, Investigational
LithiumSodium bicarbonate may increase the excretion rate of Lithium which could result in a lower serum level and potentially a reduction in efficacy.Approved
LoteprednolThe bioavailability of Loteprednol can be decreased when combined with Sodium bicarbonate.Approved
LovastatinThe serum concentration of Lovastatin can be decreased when it is combined with Sodium bicarbonate.Approved, Investigational
ME-609The bioavailability of ME-609 can be decreased when combined with Sodium bicarbonate.Investigational
MecamylamineThe serum concentration of Mecamylamine can be increased when it is combined with Sodium bicarbonate.Approved
MedrysoneThe bioavailability of Medrysone can be decreased when combined with Sodium bicarbonate.Approved
MelengestrolThe bioavailability of Melengestrol can be decreased when combined with Sodium bicarbonate.Vet Approved
MemantineThe serum concentration of Memantine can be increased when it is combined with Sodium bicarbonate.Approved, Investigational
MephedroneSodium bicarbonate may decrease the excretion rate of Mephedrone which could result in a higher serum level.Investigational
MephentermineSodium bicarbonate may decrease the excretion rate of Mephentermine which could result in a higher serum level.Approved
MesalazineThe therapeutic efficacy of Mesalazine can be decreased when used in combination with Sodium bicarbonate.Approved
MesoridazineSodium bicarbonate can cause a decrease in the absorption of Mesoridazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
MethamphetamineSodium bicarbonate may decrease the excretion rate of Methamphetamine which could result in a higher serum level.Approved, Illicit
MethenamineThe therapeutic efficacy of Methenamine can be decreased when used in combination with Sodium bicarbonate.Approved, Vet Approved
MethotrimeprazineSodium bicarbonate can cause a decrease in the absorption of Methotrimeprazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
MethoxyphenamineSodium bicarbonate may decrease the excretion rate of Methoxyphenamine which could result in a higher serum level.Experimental
Methylene blueSodium bicarbonate can cause a decrease in the absorption of Methylene blue resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
MethylphenidateSodium bicarbonate can cause an increase in the absorption of Methylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.Approved, Investigational
MethylprednisoloneThe bioavailability of Methylprednisolone can be decreased when combined with Sodium bicarbonate.Approved, Vet Approved
MevastatinThe serum concentration of Mevastatin can be decreased when it is combined with Sodium bicarbonate.Experimental
MidomafetamineSodium bicarbonate may decrease the excretion rate of Midomafetamine which could result in a higher serum level.Experimental, Illicit, Investigational
MinocyclineSodium bicarbonate can cause a decrease in the absorption of Minocycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
MisoprostolThe risk or severity of adverse effects can be increased when Sodium bicarbonate is combined with Misoprostol.Approved
MMDASodium bicarbonate may decrease the excretion rate of MMDA which could result in a higher serum level.Experimental, Illicit
MometasoneThe bioavailability of Mometasone can be decreased when combined with Sodium bicarbonate.Approved, Vet Approved
MoricizineSodium bicarbonate can cause a decrease in the absorption of Moricizine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational, Withdrawn
Mycophenolic acidSodium bicarbonate can cause a decrease in the absorption of Mycophenolic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Nalidixic AcidSodium bicarbonate can cause a decrease in the absorption of Nalidixic Acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
NCX 1022The bioavailability of NCX 1022 can be decreased when combined with Sodium bicarbonate.Investigational
NemonoxacinSodium bicarbonate can cause a decrease in the absorption of Nemonoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
NilotinibThe serum concentration of Nilotinib can be decreased when it is combined with Sodium bicarbonate.Approved, Investigational
NorfloxacinSodium bicarbonate can cause a decrease in the absorption of Norfloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Oleoyl-estroneThe bioavailability of Oleoyl-estrone can be decreased when combined with Sodium bicarbonate.Investigational
Oxolinic acidSodium bicarbonate can cause a decrease in the absorption of Oxolinic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
ParamethasoneThe bioavailability of Paramethasone can be decreased when combined with Sodium bicarbonate.Approved
PazopanibThe serum concentration of Pazopanib can be decreased when it is combined with Sodium bicarbonate.Approved
PazufloxacinSodium bicarbonate can cause a decrease in the absorption of Pazufloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
PefloxacinSodium bicarbonate can cause a decrease in the absorption of Pefloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
PenicillamineThe serum concentration of Penicillamine can be decreased when it is combined with Sodium bicarbonate.Approved
PerazineSodium bicarbonate can cause a decrease in the absorption of Perazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
PerphenazineSodium bicarbonate can cause a decrease in the absorption of Perphenazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
PhentermineSodium bicarbonate may decrease the excretion rate of Phentermine which could result in a higher serum level.Approved, Illicit
Pipemidic acidSodium bicarbonate can cause a decrease in the absorption of Pipemidic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Piromidic acidSodium bicarbonate can cause a decrease in the absorption of Piromidic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
PitavastatinThe serum concentration of Pitavastatin can be decreased when it is combined with Sodium bicarbonate.Approved
PrasteroneThe bioavailability of Prasterone can be decreased when combined with Sodium bicarbonate.Approved, Nutraceutical
Prasterone sulfateThe bioavailability of Prasterone sulfate can be decreased when combined with Sodium bicarbonate.Investigational
PravastatinThe serum concentration of Pravastatin can be decreased when it is combined with Sodium bicarbonate.Approved
PrednicarbateThe bioavailability of Prednicarbate can be decreased when combined with Sodium bicarbonate.Approved
PrednisoloneThe bioavailability of Prednisolone can be decreased when combined with Sodium bicarbonate.Approved, Vet Approved
PrednisoneThe bioavailability of Prednisone can be decreased when combined with Sodium bicarbonate.Approved, Vet Approved
PregnenoloneThe bioavailability of Pregnenolone can be decreased when combined with Sodium bicarbonate.Experimental, Investigational
ProchlorperazineSodium bicarbonate can cause a decrease in the absorption of Prochlorperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
PromazineSodium bicarbonate can cause a decrease in the absorption of Promazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
PromethazineSodium bicarbonate can cause a decrease in the absorption of Promethazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
PropericiazineSodium bicarbonate can cause a decrease in the absorption of Propericiazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
PropiopromazineSodium bicarbonate can cause a decrease in the absorption of Propiopromazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Vet Approved
PrulifloxacinSodium bicarbonate can cause a decrease in the absorption of Prulifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
PseudoephedrineSodium bicarbonate may decrease the excretion rate of Pseudoephedrine which could result in a higher serum level.Approved
QuinidineSodium bicarbonate may decrease the excretion rate of Quinidine which could result in a higher serum level.Approved
QuinineThe serum concentration of Quinine can be increased when it is combined with Sodium bicarbonate.Approved
RimexoloneThe bioavailability of Rimexolone can be decreased when combined with Sodium bicarbonate.Approved
RiociguatThe serum concentration of Riociguat can be decreased when it is combined with Sodium bicarbonate.Approved
RitobegronSodium bicarbonate may decrease the excretion rate of Ritobegron which could result in a higher serum level.Investigational
RosoxacinSodium bicarbonate can cause a decrease in the absorption of Rosoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
RosuvastatinThe serum concentration of Rosuvastatin can be decreased when it is combined with Sodium bicarbonate.Approved
RufloxacinSodium bicarbonate can cause a decrease in the absorption of Rufloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
SimvastatinThe serum concentration of Simvastatin can be decreased when it is combined with Sodium bicarbonate.Approved
SitafloxacinSodium bicarbonate can cause a decrease in the absorption of Sitafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental, Investigational
Sodium glycerophosphateSodium bicarbonate can cause a decrease in the absorption of Sodium glycerophosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Sodium phosphateSodium bicarbonate can cause a decrease in the absorption of Sodium phosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
SotalolThe serum concentration of Sotalol can be decreased when it is combined with Sodium bicarbonate.Approved
SparfloxacinSodium bicarbonate can cause a decrease in the absorption of Sparfloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
SulpirideThe serum concentration of Sulpiride can be decreased when it is combined with Sodium bicarbonate.Approved, Investigational
TemafloxacinSodium bicarbonate can cause a decrease in the absorption of Temafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Withdrawn
ThiazinamSodium bicarbonate can cause a decrease in the absorption of Thiazinam resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
ThiethylperazineSodium bicarbonate can cause a decrease in the absorption of Thiethylperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Withdrawn
ThioproperazineSodium bicarbonate can cause a decrease in the absorption of Thioproperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ThioridazineSodium bicarbonate can cause a decrease in the absorption of Thioridazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Withdrawn
TixocortolThe bioavailability of Tixocortol can be decreased when combined with Sodium bicarbonate.Approved, Withdrawn
TolevamerThe risk or severity of adverse effects can be increased when Sodium bicarbonate is combined with Tolevamer.Approved
TriamcinoloneThe bioavailability of Triamcinolone can be decreased when combined with Sodium bicarbonate.Approved, Vet Approved
TriethylenetetramineSodium bicarbonate can cause a decrease in the absorption of Triethylenetetramine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
TrifluoperazineSodium bicarbonate can cause a decrease in the absorption of Trifluoperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
TriflupromazineSodium bicarbonate can cause a decrease in the absorption of Triflupromazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
TrovafloxacinSodium bicarbonate can cause a decrease in the absorption of Trovafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational, Withdrawn
UbidecarenoneThe serum concentration of Ubidecarenone can be decreased when it is combined with Sodium bicarbonate.Approved, Investigational, Nutraceutical
UlobetasolThe bioavailability of Ulobetasol can be decreased when combined with Sodium bicarbonate.Approved
Food Interactions
Not Available

References

Synthesis Reference

Alan B. Gancy, Rustom P. Poncha, "Production of low bulk density product from sodium bicarbonate by the use of an inert gas stream." U.S. Patent US3984527, issued August, 1922.

US3984527
General References
Not Available
External Links
KEGG Drug
D01203
KEGG Compound
C12603
PubChem Compound
516892
PubChem Substance
46507049
ChemSpider
8609
ChEBI
32139
ChEMBL
CHEMBL1353
Therapeutic Targets Database
DAP000128
PharmGKB
PA451375
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Sodium_bicarbonate
ATC Codes
B05XA02 — Sodium bicarbonateB05CB04 — Sodium bicarbonate
AHFS Codes
  • 40:08.00 — Alkalinizing Agents
  • 56:04.00 — Antacids and Adsorbents
  • 40:34.00* — Hemodialysis Solution
MSDS
Download (74 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0CompletedBasic ScienceTransplantation, Kidney1
0CompletedTreatmentPulmonary Ventilation1
0Not Yet RecruitingTreatmentEdema of the cerebrum / Saline Solution, Hypertonic1
1Active Not RecruitingOtherHealthy Volunteers1
1CompletedBasic ScienceCystic Fibrosis (CF)1
1CompletedBasic ScienceHealthy Volunteers1
1CompletedPreventionChronic Kidney Disease (CKD)1
1CompletedTreatmentAcid Reflux / Gastro Oesophageal Reflux Disease1
1CompletedTreatmentGastric Emptying / Healthy Volunteers1
1CompletedTreatmentHeartburn1
1CompletedTreatmentMalignant Neoplasm of Pancreas1
1CompletedTreatmentNeoplasms, Malignant1
1RecruitingTreatmentChronic Kidney Disease (CKD) / Metabolic Acidosis / Sickle Cell Disorders1
1TerminatedSupportive CareCancers / Malignancies, Hematologic / Malignant Lymphomas / Malignant Solid Tumours / Multiple Myeloma (MM) / Neoplasms Metastasis / Pain / Tumors / Unresectable Malignant Neoplasm1
1Unknown StatusDiagnosticAdjunct to general anesthesia therapy1
1, 2Unknown StatusTreatmentPneumonia1
2CompletedOtherBowel preparation therapy1
2CompletedPreventionCardiac Surgery and Cardiopulmonary Bypass1
2CompletedPreventionContrast Induced Nephropathy (CIN)2
2CompletedPreventionKidney Injury1
2CompletedPreventionRadiographic Contrast Agent Nephropathy1
2CompletedTreatmentAcute Kidney Injury (AKI) / Congenital Heart Disease (CHD)1
2CompletedTreatmentAnaesthesia therapy / Local Infiltration1
2CompletedTreatmentCardiac Arrest / Metabolic Acidosis1
2CompletedTreatmentImpaired Renal Function / Oliguria / Systemic Inflammatory Response Syndrome (SIRS)1
2Not Yet RecruitingDiagnosticKidney Transplant; Complications1
2Not Yet RecruitingTreatmentCancers / Central Venous Catheterization1
2RecruitingTreatmentChronic Kidney Disease (CKD)1
2TerminatedTreatmentAcute Kidney Injury (AKI)1
2, 3CompletedPreventionContrast Induced Nephropathy (CIN)1
2, 3CompletedTreatmentChronic Kidney Disease (CKD)1
2, 3RecruitingTreatmentChronic Kidney Disease (CKD) / Metabolic Acidosis1
2, 3TerminatedPreventionCardiopulmonary Bypass / Surgery, Cardiac1
2, 3Unknown StatusDiagnosticDetection of the Correct Position of Intravenous Line1
2, 3Unknown StatusDiagnosticDrug Extravasation / Infiltration1
3Active Not RecruitingTreatmentMyocardial Injury After Noncardiac Surgery (MINS)1
3CompletedNot AvailableBowel Preparation for Colonoscopy1
3CompletedNot AvailableColonoscopy1
3CompletedNot AvailableContrast Induced Nephropathy (CIN) / Kidney Diseases1
3CompletedNot AvailableGastric Acid / Human Experimentation2
3CompletedNot AvailableIntragastric Acidity1
3CompletedNot AvailableLocal Anesthesia2
3CompletedDiagnosticBowel Preparation for Colonoscopy1
3CompletedDiagnosticBowel Preparation, Efficacy, Tolerability, Safety1
3CompletedPreventionChronic Kidney Disease (CKD)1
3CompletedPreventionRenal Failure1
3CompletedSupportive CareColon Adenomas / Colorectal Cancers1
3CompletedTreatmentCataracts2
3CompletedTreatmentColonoscopy1
3CompletedTreatmentHuman Experimentation1
3CompletedTreatmentMalignant Neoplasm of Colon1
3CompletedTreatmentOccasional Constipation1
3CompletedTreatmentReflux, Gastroesophageal1
3RecruitingOtherDigestive System Diseases1
3RecruitingPreventionAcute Kidney Injury (AKI) / Contrast media reaction1
3RecruitingTreatmentHealthy Volunteers1
3RecruitingTreatmentMetabolic Acidosis1
3TerminatedPreventionContrast Induced Kidney Injury1
3TerminatedPreventionHypopharynx Cancer / Oropharynx Cancers1
3Unknown StatusDiagnosticColonoscopy1
3Unknown StatusPreventionAcute Renal Failure (ARF)1
3Unknown StatusPreventionChronic Kidney Disease (CKD)1
3Unknown StatusPreventionKidney Failures, Acute1
4Active Not RecruitingTreatmentDiabetes, Diabetes Mellitus Type 1 / Diabetic Kidney Disease / Diabetic Nephropathies1
4CompletedNot AvailableColonoscopy1
4CompletedNot AvailableNormal Healthy Subject Population1
4CompletedDiagnosticAnatomic renal artery stenosis / Chronic Kidney Disease (CKD) / Pulmonary Cancer / Pulmonary Embolism (PE)1
4CompletedPreventionContrast Induced Acute Kidney Injury1
4CompletedPreventionContrast Induced Nephropathy (CIN)2
4CompletedPreventionContrast media reaction / Kidney Diseases1
4CompletedPreventionEmergent Coronary Procedure1
4CompletedPreventionMarginal Ulcers1
4CompletedPreventionPulmonary Embolism (PE) / Radiographic Contrast Agent Nephropathy1
4CompletedPreventionProphylaxis of Contrast-induced nephropathy1
4CompletedSupportive CareEnd-Stage Renal Disease (ESRD)1
4CompletedSupportive CarePain1
4CompletedTreatmentColonoscopy2
4CompletedTreatmentContrast Induced Nephropathy (CIN)1
4CompletedTreatmentErosive Esophagitis(EE)1
4CompletedTreatmentHeartburn1
4CompletedTreatmentMalignant Neoplasm of Colon1
4CompletedTreatmentPreparation for Colonoscopy1
4Enrolling by InvitationPreventionOral Mucositis1
4Enrolling by InvitationTreatmentLocal Anesthesia1
4Not Yet RecruitingDiagnosticBowel Preparation Solutions1
4Not Yet RecruitingHealth Services ResearchColorectal Cancers1
4RecruitingPreventionAcute Kidney Injury (AKI)1
4RecruitingPreventionAcute Kidney Injury (AKI) / Aortic Valve Disorder / Chronic Kidney Disease (CKD) / Contrast Induced Nephropathy (CIN)1
4RecruitingTreatmentSubjets Requiring a Colonoscopy1
4RecruitingTreatmentVaricosities of the great saphenous vein1
4TerminatedPreventionContrast Media / Kidney Failures, Acute1
4Unknown StatusHealth Services ResearchColonoscopy1
4Unknown StatusTreatmentContrast Induced Nephropathy (CIN)1
4Unknown StatusTreatmentSudden Cardiac Arrest1
Not AvailableActive Not RecruitingDiagnosticDiabetes Mellitus (DM)1
Not AvailableActive Not RecruitingTreatmentChronic Renal Insufficiency / Diabetes Mellitus (DM)1
Not AvailableCompletedNot AvailableEffectiveness of SMS to Fix PC Interval1
Not AvailableCompletedNot AvailableSpinal Cord Injuries (SCI)1
Not AvailableCompletedNot AvailableThe Timing of Bowel Preparation in Outpatient Colonoscopy1
Not AvailableCompletedPreventionAcute Kidney Injury (AKI)1
Not AvailableCompletedPreventionAcute Renal Failure Contrast Nephropathy1
Not AvailableCompletedPreventionContrast Induced Nephropathy (CIN)1
Not AvailableCompletedPreventionDysglycaemia / Insulin Resistance / Type 2 Diabetes Mellitus1
Not AvailableCompletedTreatmentCardiac Arrest1
Not AvailableCompletedTreatmentChronic Kidney Disease (CKD) / Metabolic Acidosis1
Not AvailableCompletedTreatmentHepatic Encephalopathy / Liver Cirrhosis / Portosystemic Encephalopathy / PSE1
Not AvailableCompletedTreatmentOral Hygiene1
Not AvailableNot Yet RecruitingTreatmentAsymptomatic Hyperuricemia / Gout Acute1
Not AvailableNot Yet RecruitingTreatmentChronic Kidney Disease (CKD) / Metabolic Acidosis1
Not AvailableRecruitingDiagnosticColonoscopy1
Not AvailableRecruitingHealth Services ResearchAcute Kidney Injury (AKI)1
Not AvailableRecruitingScreeningColonoscopy1
Not AvailableRecruitingTreatmentHealthy Volunteers1
Not AvailableTerminatedPreventionContrast Induced Nephropathy (CIN)1
Not AvailableTerminatedSupportive CareNeoplasm Related Pain (Acute) (Chronic)1
Not AvailableUnknown StatusDiagnosticBowel Preparation for Colonoscopy1
Not AvailableUnknown StatusDiagnosticPreserving Kidney Function in People Who Are at High Risk of Developing Contrast-induced Nephropathy1
Not AvailableUnknown StatusTreatmentEsophagus, Barrett / Reflux, Gastroesophageal1
Not AvailableWithdrawnScreeningPatients Undergoing Screening or Surveillance Colonoscopy1
Not AvailableWithdrawnTreatmentAltered Mental Status / AMS / HE / Hepatic Encephalopathy / Liver Cirrhosis1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Dosage forms
FormRouteStrength
LiquidTopical50 mg/mL
LiquidTopical5 g/100g
Powder, for solutionIntraocular
LiquidOral525 mg/15mL
Powder, for solutionOral1 g/g
LiquidTopical5 g/100mL
PowderOral100 %
Powder, for solutionHemodialysis
Kit; powder, for solution; tablet, delayed releaseOral
LiquidHemodialysis81.25 g
LiquidHemodialysis72 g
LiquidHemodialysis80.68 g
SolutionHemodialysis80.7 g
SolutionHemodialysis
SolutionHemodialysis81.3 g
LiquidHemodialysis
PowderHemodialysis1250 g
PowderHemodialysis720 g
Kit; powder, for solutionHemodialysis
Powder, for solutionHemodialysis750 g
Powder, for solutionHemodialysis900 g
Granule, effervescentOral
Granule, effervescentOral1.02 g/5g
Granule, effervescentOral1.8 g
Granule, effervescentOral269 mg
Kit; solutionIntraocular
LiquidIntravenous
SuppositoryRectal
Powder, for solutionNasogastric
Kit
PowderNasal
SolutionNasal
PowderOral2.6 g/2.6g
LiquidOral25 mg/mL
InjectionIntrathecal
PowderTopical165 g/300g
PowderHemodialysis6 kg
Powder, for solutionHemodialysis650 g
PowderOral1000 mg/g
GranuleOral
Kit
Kit; solutionIntraocular; Irrigation
Injection, solutionIntravenous.2 g/5mL
Tablet, effervescentOral
SolutionOral
Capsule, gelatin coatedOral
Powder, for suspensionOral
Liquid; mouthwashOral
SolutionIntravenous
Powder, for solutionOral
SolutionHemodialysis; Intravenous
LiquidOral
Powder, for solutionNasal
KitNasal
TabletOral
InjectionIntravenous84 mg/mL
InjectionParenteral84 mg/mL
Injection, solutionIntravenous42 mg/mL
Injection, solutionIntravenous44.6 meq/50mL
Injection, solutionIntravenous75 mg/mL
Injection, solutionIntravenous84 mg/mL
PowderOral; Topical100 %
SolutionIntravenous42 mg/mL
SolutionParenteral84 mg/mL
TabletOral650 mg/1
Tablet, orally disintegratingOral650 mg/1
TabletOral648 mg/1
TabletOral324 mg/1
TabletOral325 mg/1
LiquidIntravenous50 mg
SolutionIntravenous5 g
PowderOral1 g/g
PowderOral2.616 g/2.616g
Powder, for solutionHemodialysis672 g
LiquidIntravenous42 mg
LiquidIntravenous75 mg
LiquidIntravenous84 mg
SolutionIntravenous75 mg
SolutionIntravenous4.2 g
SolutionIntravenous42 mg
SolutionIntravenous84 mg
TabletOral300 mg
TabletOral600 mg
PowderHemodialysis650 g
PowderHemodialysis
Powder, for solutionHemodialysis1100 g
Powder, for solutionHemodialysis760 g
CapsuleOral
PowderOral
KitOral
CreamTopical50 mg/g
Powder, for solutionNasogastric; Oral
Granule, for solutionNasal
Prices
Unit descriptionCostUnit
Golytely 236 gm Solution28.0USD bottle
Colyte 240 gm Solution26.0USD bottle
Golytely 227.1 gm Solution Packet21.85USD packet
Colyte-Flavored 240 gm Solution18.17USD bottle
Elliotts b solution ampule4.71USD ml
Sodium bicarb 4.2% vial1.45USD ml
Neut 4% vial0.92USD ml
Bss plus eye solution0.2USD ml
Sodium bicarb 650 mg tablet0.07USD tablet
Antacid 650 mg tablet0.05USD tablet
Antacid 325 mg tablet0.04USD tablet
Sodium bicarb 325 mg tablet0.04USD tablet
Sodium bicarb 7.5% vial0.04USD ml
Sodium bicarbonate powder0.03USD g
Sodium bicarb 8.4% vial0.02USD ml
Sodium bicarbonate 5% inj0.02USD ml
Colyte with flavor packets0.01USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US6489346No1996-07-162016-07-16Us
US6699885No1996-07-162016-07-16Us
USRE45198No1996-07-162016-07-16Us
US6645988No1996-07-162016-07-16Us
US7399772No1996-07-162016-07-16Us
US5945449No1997-10-312017-10-31Us
US7300674No2003-03-042023-03-04Us
US7291324No2002-10-222022-10-22Us
US5840737No1996-07-152016-07-15Us
US6780882No1996-07-152016-07-15Us
US7084130No2001-11-292021-11-29Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)Decomposes around 50 °CNot Available
water solubility1E+005 mg/L (at 25 °C)MERCK INDEX (1996)
pKa6.3Not Available
Predicted Properties
PropertyValueSource
Water Solubility764.0 mg/mLALOGPS
logP-0.06ALOGPS
logP0.25ChemAxon
logS0.96ALOGPS
pKa (Strongest Acidic)6.05ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area60.36 Å2ChemAxon
Rotatable Bond Count0ChemAxon
Refractivity20.34 m3·mol-1ChemAxon
Polarizability3.86 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9292
Blood Brain Barrier+0.936
Caco-2 permeable-0.5321
P-glycoprotein substrateNon-substrate0.8785
P-glycoprotein inhibitor INon-inhibitor0.9903
P-glycoprotein inhibitor IINon-inhibitor0.9931
Renal organic cation transporterNon-inhibitor0.9563
CYP450 2C9 substrateNon-substrate0.8326
CYP450 2D6 substrateNon-substrate0.9017
CYP450 3A4 substrateNon-substrate0.8144
CYP450 1A2 substrateNon-inhibitor0.9053
CYP450 2C9 inhibitorNon-inhibitor0.9337
CYP450 2D6 inhibitorNon-inhibitor0.9401
CYP450 2C19 inhibitorNon-inhibitor0.9461
CYP450 3A4 inhibitorNon-inhibitor0.9774
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9911
Ames testNon AMES toxic0.9285
CarcinogenicityNon-carcinogens0.5181
BiodegradationReady biodegradable0.9636
Rat acute toxicity1.9204 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9596
hERG inhibition (predictor II)Non-inhibitor0.9866
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as organic carbonic acids. These are compounds comprising the carbonic acid functional group.
Kingdom
Organic compounds
Super Class
Organic acids and derivatives
Class
Organic carbonic acids and derivatives
Sub Class
Organic carbonic acids
Direct Parent
Organic carbonic acids
Alternative Parents
Carbonate salts / Organic sodium salts / Organic oxides / Hydrocarbon derivatives / Carbonyl compounds
Substituents
Carbonate salt / Carbonic acid / Organic alkali metal salt / Organic oxygen compound / Organic oxide / Hydrocarbon derivative / Organic sodium salt / Organic salt / Organooxygen compound / Carbonyl group
Molecular Framework
Aliphatic acyclic compounds
External Descriptors
one-carbon compound, organic sodium salt (CHEBI:32139)

Targets

1. Hydrogen ions
Kind
Small molecule
Organism
Not Available
Pharmacological action
Yes
Actions
Neutralizer
References
  1. Nudel DB, Peterson BJ, Buckley BJ, Kaplan NA, Weinhaouse E, Gootman N: Comparative effects of bicarbonate and dichloroacetate in newborn swine with hypoxic lactic acidosis. Dev Pharmacol Ther. 1990;15(2):86-93. [PubMed:1964114]
  2. Roderick P, Willis NS, Blakeley S, Jones C, Tomson C: Correction of chronic metabolic acidosis for chronic kidney disease patients. Cochrane Database Syst Rev. 2007 Jan 24;(1):CD001890. [PubMed:17253467]
  3. Balali-Mood M, Balali-Mood K: Neurotoxic disorders of organophosphorus compounds and their managements. Arch Iran Med. 2008 Jan;11(1):65-89. [PubMed:18154426]
  4. Vaughan-Jones RD, Spitzer KW: Role of bicarbonate in the regulation of intracellular pH in the mammalian ventricular myocyte. Biochem Cell Biol. 2002;80(5):579-96. [PubMed:12440699]
  5. Levraut J, Giunti C, Ciebiera JP, de Sousa G, Ramhani R, Payan P, Grimaud D: Initial effect of sodium bicarbonate on intracellular pH depends on the extracellular nonbicarbonate buffering capacity. Crit Care Med. 2001 May;29(5):1033-9. [PubMed:11378618]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Sodium:bicarbonate symporter activity
Specific Function
Electrogenic sodium/bicarbonate cotransporter with a Na(+):HCO3(-) stoichiometry varying from 1:2 to 1:3. May regulate bicarbonate influx/efflux at the basolateral membrane of cells and regulate in...
Gene Name
SLC4A4
Uniprot ID
Q9Y6R1
Uniprot Name
Electrogenic sodium bicarbonate cotransporter 1
Molecular Weight
121459.38 Da
References
  1. Bernardo AA, Bernardo CM, Espiritu DJ, Arruda JA: The sodium bicarbonate cotransporter: structure, function, and regulation. Semin Nephrol. 2006 Sep;26(5):352-60. [PubMed:17071329]
  2. Kurtz I, Petrasek D, Tatishchev S: Molecular mechanisms of electrogenic sodium bicarbonate cotransport: structural and equilibrium thermodynamic considerations. J Membr Biol. 2004 Jan 15;197(2):77-90. [PubMed:15014910]
  3. Soleimani M: Functional and molecular properties of Na+:HCO-3 cotransporters (NBC). Minerva Urol Nefrol. 2003 Jun;55(2):131-40. [PubMed:12847417]
  4. Soleimani M: Na+:HCO3- cotransporters (NBC): expression and regulation in the kidney. J Nephrol. 2002 Mar-Apr;15 Suppl 5:S32-40. [PubMed:12027220]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Sodium:bicarbonate symporter activity
Specific Function
Electroneutral sodium- and bicarbonate-dependent cotransporter with a Na(+):HCO3(-) 1:1 stoichiometry. Regulates intracellular pH and may play a role in bicarbonate salvage in secretory epithelia. ...
Gene Name
SLC4A7
Uniprot ID
Q9Y6M7
Uniprot Name
Sodium bicarbonate cotransporter 3
Molecular Weight
136042.595 Da
References
  1. Bernardo AA, Bernardo CM, Espiritu DJ, Arruda JA: The sodium bicarbonate cotransporter: structure, function, and regulation. Semin Nephrol. 2006 Sep;26(5):352-60. [PubMed:17071329]
  2. Kurtz I, Petrasek D, Tatishchev S: Molecular mechanisms of electrogenic sodium bicarbonate cotransport: structural and equilibrium thermodynamic considerations. J Membr Biol. 2004 Jan 15;197(2):77-90. [PubMed:15014910]
  3. Soleimani M: Functional and molecular properties of Na+:HCO-3 cotransporters (NBC). Minerva Urol Nefrol. 2003 Jun;55(2):131-40. [PubMed:12847417]
  4. Soleimani M: Na+:HCO3- cotransporters (NBC): expression and regulation in the kidney. J Nephrol. 2002 Mar-Apr;15 Suppl 5:S32-40. [PubMed:12027220]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Sodium:bicarbonate symporter activity
Specific Function
Mediates electroneutral sodium- and carbonate-dependent chloride-HCO3(-) exchange with a Na(+):HCO3(-) stoichiometry of 2:1. Plays a major role in pH regulation in neurons. May be involved in cell ...
Gene Name
SLC4A8
Uniprot ID
Q2Y0W8
Uniprot Name
Electroneutral sodium bicarbonate exchanger 1
Molecular Weight
122936.66 Da
References
  1. Bernardo AA, Bernardo CM, Espiritu DJ, Arruda JA: The sodium bicarbonate cotransporter: structure, function, and regulation. Semin Nephrol. 2006 Sep;26(5):352-60. [PubMed:17071329]
  2. Kurtz I, Petrasek D, Tatishchev S: Molecular mechanisms of electrogenic sodium bicarbonate cotransport: structural and equilibrium thermodynamic considerations. J Membr Biol. 2004 Jan 15;197(2):77-90. [PubMed:15014910]
  3. Soleimani M: Functional and molecular properties of Na+:HCO-3 cotransporters (NBC). Minerva Urol Nefrol. 2003 Jun;55(2):131-40. [PubMed:12847417]
  4. Soleimani M: Na+:HCO3- cotransporters (NBC): expression and regulation in the kidney. J Nephrol. 2002 Mar-Apr;15 Suppl 5:S32-40. [PubMed:12027220]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Sodium:bicarbonate symporter activity
Specific Function
Mediates sodium- and bicarbonate-dependent electrogenic sodium bicarbonate cotransport, with a Na(+):HCO3(-) stoichiometry of 2:1. May have a housekeeping function in regulating the pH of tissues i...
Gene Name
SLC4A5
Uniprot ID
Q9BY07
Uniprot Name
Electrogenic sodium bicarbonate cotransporter 4
Molecular Weight
126254.04 Da
References
  1. Bernardo AA, Bernardo CM, Espiritu DJ, Arruda JA: The sodium bicarbonate cotransporter: structure, function, and regulation. Semin Nephrol. 2006 Sep;26(5):352-60. [PubMed:17071329]
  2. Kurtz I, Petrasek D, Tatishchev S: Molecular mechanisms of electrogenic sodium bicarbonate cotransport: structural and equilibrium thermodynamic considerations. J Membr Biol. 2004 Jan 15;197(2):77-90. [PubMed:15014910]
  3. Soleimani M: Functional and molecular properties of Na+:HCO-3 cotransporters (NBC). Minerva Urol Nefrol. 2003 Jun;55(2):131-40. [PubMed:12847417]
  4. Soleimani M: Na+:HCO3- cotransporters (NBC): expression and regulation in the kidney. J Nephrol. 2002 Mar-Apr;15 Suppl 5:S32-40. [PubMed:12027220]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Sodium:bicarbonate symporter activity
Specific Function
Electrogenic sodium/bicarbonate cotransporter in exchange for intracellular chloride. Plays an important role in regulating intracellular pH (By similarity).
Gene Name
SLC4A10
Uniprot ID
Q6U841
Uniprot Name
Sodium-driven chloride bicarbonate exchanger
Molecular Weight
125945.115 Da
References
  1. Bernardo AA, Bernardo CM, Espiritu DJ, Arruda JA: The sodium bicarbonate cotransporter: structure, function, and regulation. Semin Nephrol. 2006 Sep;26(5):352-60. [PubMed:17071329]
  2. Kurtz I, Petrasek D, Tatishchev S: Molecular mechanisms of electrogenic sodium bicarbonate cotransport: structural and equilibrium thermodynamic considerations. J Membr Biol. 2004 Jan 15;197(2):77-90. [PubMed:15014910]
  3. Soleimani M: Functional and molecular properties of Na+:HCO-3 cotransporters (NBC). Minerva Urol Nefrol. 2003 Jun;55(2):131-40. [PubMed:12847417]
  4. Soleimani M: Na+:HCO3- cotransporters (NBC): expression and regulation in the kidney. J Nephrol. 2002 Mar-Apr;15 Suppl 5:S32-40. [PubMed:12027220]

Drug created on July 08, 2007 10:59 / Updated on January 15, 2018 08:53